Jeffrey Holzbeierlein

Jeffrey Holzbeierlein is a specialist in non-muscle invasive bladder cancer and has contributed to clinical research on BCG therapy optimization, BCG-unresponsive disease management, and surveillance strategies. He has been involved in clinical trials evaluating novel intravesical agents for BCG failure including pembrolizumab and nadofaragene firadenovec. He serves on AUA guideline panels for bladder cancer and has been an active educator in urological oncology. His work addresses the significant unmet need in patients who fail or are intolerant of BCG therapy.